Human Lambda Free Light Chain Assay
Diazyme's Human Lambda Free Light Chain (FLC) assay has excellent across the Analytical Measuring Interval (AMI) in standard mode: 3.5 – 200 mg/L ; extended mode: 3.5 – 4000 mg/L. The method comparison gave a linear regression coefficient of 0.972, a slope of 1.054 and y-intercept of 0.636 mg/L. Precision of the assay was evaluated according to the CLSI EP5-A guidelines and has a Within-Run precision from 1.1% - 6.5% and a Total Precision of 1.1% - 11.4%. The Lambda assay displays outstanding sensitivity with an LOD of 2.8 (Export 2.3) mg/L; LOQ of 3.5 mg/L; and a LOB determined to be 1.6 (Export 1.1) mg/L.
Human Lambda (λ) Free Light Chain Assay is based on a latex enhanced immunoturbidimetric assay. Lambda FLC in the sample binds to specific anti-Lambda FLC antibody, which is coated on latex particles, and causes agglutination. The degree of the turbidity caused by agglutination can be measured optically and is proportional to the amount of Lambda FLC in the sample. The instrument calculates the Lambda FLC concentration by interpolation of obtained signal of a 6-point calibration curve prepared from calibrators of known concentrations.
The Diazyme Human Lambda (λ) Free Light Chain Assay is intended as a latex particle enhanced immunoturbidimetric assay for the quantitative determination of Lambda Free Light Chain (FLC) concentrations in serum on validated analyzers. The measurement of Lambda FLC in conjunction with Kappa FLC aids in the diagnosis and monitoring of multiple myeloma in conjunction with other laboratory and clinical findings. For in-vitro diagnostic use only.
|Kit||DZ170A||R1/R2 (Dual Vial Liquid Stable, Immunoturbidimetric)
Cal: 5 level (Included with kit)
|Control||DZ169A-CON||Con: 2 Level|
Health Canada Registered